scholarly journals Extravascular Volume Overload

2020 ◽  
Author(s):  
2017 ◽  
Vol 9 (4) ◽  
Author(s):  
Bilal Katipoglu ◽  
Zeynep Katipoğlu ◽  
Ihsan Ates ◽  
Gokhan Yirgin ◽  
Burak Furkan Demir ◽  
...  

POEMS syndrome is an important paraneoplastic syndrome associated with multisystem involvement. Extravascular volume overload like pericardial effusion and ascites has a broad differential diagnosis. In addition, it may be initial presentation of disease. For that reason, this case report is highlight to warn of different forms of presentation of poems syndrome.


2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Shuji Ueda ◽  
Sayoko Yonemoto ◽  
Kazumasa Oka ◽  
Naohiko Fujii ◽  
Keiichi Nakata ◽  
...  

POEMS syndrome is a multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. POEMS syndrome is a rare cause of refractory ascites. We report the case of a patient with POEMS syndrome presenting with massive ascites who was treated with very-low-dose lenalidomide and dexamethasone. A 57-year-old Japanese man was admitted to our hospital with pleural effusion, massive ascites, and leg edema. The diagnosis of POEMS syndrome was made based on the combination of the following findings: peripheral neuropathy, organomegaly, endocrinopathy, serum monoclonal protein elevation, skin changes, plasma VEGF elevation, and evidence of extravascular volume overload. Renal dysfunction induced by biopsy-proven renal involvement of POEMS syndrome was observed. Massive ascites of the patient dramatically diminished with long-time treatment of very-low-dose lenalidomide and dexamethasone. Lenalidomide seems to be a very promising therapy for POEMS syndrome presenting with extravascular volume overload such as edema, pleural effusion, and ascites. Very-low-dose lenalidomide might be effective especially for the patients with POEMS-related nephropathy.


Blood ◽  
2011 ◽  
Vol 117 (24) ◽  
pp. 6445-6449 ◽  
Author(s):  
Jian Li ◽  
Wei Zhang ◽  
Li Jiao ◽  
Ming-Hui Duan ◽  
Hong-Zhi Guan ◽  
...  

Abstract POEMS syndrome is a rare clonal plasma cell disorder without standard treatment. Based on the efficacy and low toxicity of a combination of melphalan and dexamethasone (MDex) for light chain amyloidosis, we conducted a prospective study of MDex treatment for patients with newly diagnosed POEMS syndrome. Thirty-one patients (19 men) were enrolled and the median age at the time of diagnosis was 44 years (range, 32-68 years). All patients received 12 cycles of MDex treatment. Twenty-five patients (80.6%) achieved hematologic response including 12 (38.7%) complete remission and 13 (41.9%) partial remission. Of all 31 patients, the neurologic response rate was 100%, assessed by overall neuropathy limitation scale (ONLS). The initial neurologic response was observed in 24 patients (77.4%) at 3 months after treatment and the median time to maximal neurologic response was 12 months (range, 3-15 months). Moreover, MDex substantially improved the level of serum vascular endothelial growth factor and relieved organomegaly, extravascular volume overload, and pulmonary hypertension. Only 6 patients (19.3%) suffered from grade 3 adverse events during treatment. All patients are alive and free of neurologic relapse after the median follow-up time of 21 months. Therefore, MDex is an effective and well-tolerated treatment option for patients with newly diagnosed POEMS syndrome.


2019 ◽  
Vol 25 (8) ◽  
pp. S21
Author(s):  
N. Gomez ◽  
B. Stewart ◽  
J. Barnett ◽  
A. Thomas ◽  
E. Wycallis ◽  
...  

1999 ◽  
Vol 1 ◽  
pp. S101-S101
Author(s):  
O FOKINA ◽  
N TVERDOKHLEBOV ◽  
V SANDRIKOV ◽  
L KOUZNETZOVA

2015 ◽  
Vol 53 (01) ◽  
Author(s):  
A Wannhoff ◽  
T Hippchen ◽  
K Friedrich ◽  
C Rupp ◽  
KH Weiss ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document